Picard Medical Q1 Revenue Soars 85% with Positive 24% Gross Margin

In 2025, Picard Medical achieved total revenue of $4.9 million, up 12.5% year-over-year, with product revenue comprising 96% of sales. The company completed an IPO raising $17.4 million net, secured $9.7 million in debt financing, and ended the year with $11.5 million in cash versus $0.1 million at end-2024.

In Q1 2026, revenue increased 85% to $1.2 million while gross profit turned positive at a 24% margin compared to a negative 58% margin a year earlier. During the quarter, approximately $7.4 million of senior secured debt was repaid in cash, $2.1 million was settled via equity, and subsequent fundraising raised $5.0 million in gross proceeds while simplifying the capital structure.

The Emperor total artificial heart entered first-in-animal trials in November 2025, with second-generation model testing completed successfully and achieving physiological pulsatile flow rates. The company holds multiple patents on the fully implantable, driverless design and anticipates seeking regulatory approval as early as 2028, pending non-clinical and regulatory outcomes.

Picard Medical has until June 7, 2026 to submit an NYSE American compliance plan after receiving notices on equity requirements. The company is pursuing four initiatives—gross margin expansion, operational efficiency, expanded indications via a pending FDA supplement, and commercial execution—to strengthen its balance sheet and move toward long-term sustainability.